Attendees at this year’s HPS Family Conference will learn about genetics from one of the world’s leading experts on albinism. Dr. Murray Brilliant will explain how HPS is inherited by using pool noodles to represent genes. His presentation was a big hit at the NOAH meeting last summer. He will also be presenting at NOAH New York, to be co-located with the HPS Family Conference.
Dr. Murray H. Brilliant, Ph.D., has been the Lindholm Professor of Genetics in the Department of Pediatrics at the University of Arizona College of Medicine since 1997. Dr. Brilliant chairs the Research Steering Committee of the Department of Pediatrics and is the Director of the Genetics Graduate Program at the University of Arizona. He has served on the editorial boards of various scientific journals and has served on numerous NIH review panels. Dr. Brilliant received his Ph.D. in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder in 1984. He has held faculty positions at The Jackson Laboratory in Bar Harbor, Maine (1986-1989) and at The Fox Chase Cancer Center in Philadelphia, Pennsylvania (1989-1997). Dr. Brilliant has over 17 years experience in the molecular genetics of pigmentation in mice and humans, with over 50 publications in this area. In particular, his efforts have led to the identification of two of the four known genes involved in oculocutaneous albinism. Dr. Brilliant’s laboratory is one of the leading centers working on the functional analysis of the proteins involved in albinism and the effects of genetic variations in these genes. Recently, his laboratory has been working to develop a novel gene therapy approach to address the problems associated with vision in people with albinism.
Dr. Murray H. Brilliant, Ph.D., has been the Lindholm Professor of Genetics in the Department of Pediatrics at the University of Arizona College of Medicine since 1997. Dr. Brilliant chairs the Research Steering Committee of the Department of Pediatrics and is the Director of the Genetics Graduate Program at the University of Arizona. He has served on the editorial boards of various scientific journals and has served on numerous NIH review panels. Dr. Brilliant received his Ph.D. in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder in 1984. He has held faculty positions at The Jackson Laboratory in Bar Harbor, Maine (1986-1989) and at The Fox Chase Cancer Center in Philadelphia, Pennsylvania (1989-1997). Dr. Brilliant has over 17 years experience in the molecular genetics of pigmentation in mice and humans, with over 50 publications in this area. In particular, his efforts have led to the identification of two of the four known genes involved in oculocutaneous albinism. Dr. Brilliant’s laboratory is one of the leading centers working on the functional analysis of the proteins involved in albinism and the effects of genetic variations in these genes. Recently, his laboratory has been working to develop a novel gene therapy approach to address the problems associated with vision in people with albinism.
For more information about the conference, go to: www.hpsnetwork.org.
Comments